Zimbabwe has declined a major US health deal worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive data.
This move came to light following a internal memorandum dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman has since clarified that the United States was requesting biological samples for research and commercial purposes while refused to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more negotiations to secure a deal suitable to both sides so the country's vital HIV programme can proceed.
Broader Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a court halted a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
Based on reports, Sixteen nations in Africa have so far agreed to similar agreements, representing more than $18.3bn in new funding.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information indefinitely, without any corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"In essence, our country would supply the raw materials for scientific discovery without any assurance that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how subsequent co-operation could be designed in a manner that respects the sovereignty and interests of both nations."
Health Experts Response
A leading public health body said it acknowledged the government's concerns, but recommended that talks need to persist considering much of the country's HIV programmes were funded by foreign aid.
"If specific concerns arise, including those involving information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group said.
This impasse highlights the continuing debate between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.